Scheinberg M, Gonçalves DP, Laurindo IM.
Anti-TNF Agents Inducing Psoriasis: A Recognized Adverse Effect.
J Clin Rheumatol. 2008 Apr;14(2):130.

Tomas D, Vučić M, Situm M, Krušlin B.
The expression of syndecan-1 in psoriatic epidermis.
Arch Dermatol Res. 2008 Apr 2

Huang W, Cordoro KM, Taylor SL, Feldman SR.
To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis.
J Am Acad Dermatol. 2008 Apr 1

Chen M, Chen ZQ, Cui PG, Yao X, Li YM, Li AS, Gong JQ, Cao YH.
The methylation pattern of p16(INK4a) gene promoter in psoriatic epidermis and its clinical significance.
Br J Dermatol. 2008 Mar 28

Rahman P, O'Rielly DD.
Psoriatic arthritis: genetic susceptibility and pharmacogenetics.
Pharmacogenomics. 2008 Feb;9(2):195-205

Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG; for the National Psoriasis Foundation.
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
J Am Acad Dermatol. 2008 Feb 27

Mirmohammadsadegh A, Tartler U, Michel G, Baer A, Walz M, Wolf R, Ruzicka T, Hengge UR.
HAX-1, identified by differential display reverse transcription polymerase chain reaction, is overexpressed in lesional psoriasis.
J Invest Dermatol. 2003 Jun;120(6):1045-51.

Mirmohammadsadegh A, Tartler U, Michel G, Baer A, Walz M, Wolf R, Ruzicka T, Hengge UR.
HAX-1, identified by differential display reverse transcription polymerase chain reaction, is overexpressed in lesional psoriasis.
J Invest Dermatol. 2003 Jun;120(6):1045-51.

Mirmohammadsadegh A, Tschakarjan E, Ljoljic A, Bohner K, Michel G, Ruzicka T, Goos M, Hengge UR.
Calgranulin C is overexpressed in lesional psoriasis.
J Invest Dermatol. 2000 Jun;114(6):1207-8